MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
CTI BioPharma Corp. Operating Expenses 2011-2026 | CTIC
Annual Operating Expenses CTI BioPharma Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 47.8 M | 43.3 M | 57.6 M | 64.3 M | 105 M | 131 M | 145 M | 75.9 M | 101 M | 73.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 145 M | 43.3 M | 84.4 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.37 | -8.67 % | $ 350 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.43 | -2.69 % | $ 8.25 B |  Australia |
 |
Biogen
BIIB
|
5.39 B | $ 177.93 | -4.15 % | $ 25.9 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
731 M | $ 65.89 | -0.06 % | $ 8.81 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
17.6 B | $ 94.4 | 0.82 % | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 214.55 | 2.77 % | $ 5 B |  Danmark |
 |
Codiak BioSciences
CDAK
|
92.5 M | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
12.2 B | $ 55.84 | 0.13 % | $ 113 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
447 M | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M |  Canada |
 |
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.86 | - | $ 908 M |  Israel |
 |
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
93.4 M | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
512 M | $ 106.88 | 4.6 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 4.18 | -1.65 % | $ 9.1 B | Israel |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Biosciences
CBIO
|
176 M | $ 11.09 | 1.0 % | $ 730 M | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Coherus BioSciences
CHRS
|
231 M | $ 1.69 | 2.12 % | $ 159 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
168 M | $ 28.99 | -1.39 % | $ 1.4 B | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 25.71 | 0.16 % | $ 1.66 M | USA |
 |
Cellectis S.A.
CLLS
|
109 M | $ 4.24 | -0.47 % | $ 116 M |  France |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 9.57 | -0.78 % | $ 1.55 B | Britain |